Compare Adaptive Biotechnologies Corp (ADPT) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Infosys Limited — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Infosys Limited trades at $12.32 (market cap $50.55B). The key difference: Infosys Limited is far larger — about 12.5× Adaptive Biotechnologies Corp's market cap, and Infosys Limited pays a 4.16% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | INFY | |
|---|---|---|
Market Cap | $4.04B | $50.55B |
Sector | Health | Technology |
52-Week High | $25.45 | $20.22 |
52-Week Low | $12.30 | $10.49 |
Enterprise Value | $4.10B | $48.30B |
Dividend Yield | — | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
INFY trades at $12.215, down 2.75% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators including RSI above 76. Fundamentally, the company maintains strong profitability with 16.37% net margins and 32.12% ROE, though Q2 2026 earnings missed expectations. Recent news highlights strategic AI collaborations with Metsä Group and Sentara Healthcare while Q1 2027 results showed revenue challenges but margin resilience.
The outlook remains cautious with analyst consensus at Hold (55%) and $11.05 price target below current levels. Key opportunities include growing AI revenue streams and strong cash flow generation, while risks involve revenue growth volatility and competitive IT services market pressures. The stock faces near-term headwinds from lowered growth guidance but maintains solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
